Multiple Evanescent White Dot Syndrome Following Adenovirus Vector-Based COVID-19 Vaccine (Covishield)

Ocul Immunol Inflamm. 2023 Aug;31(6):1299-1304. doi: 10.1080/09273948.2023.2192271. Epub 2023 Apr 12.

Abstract

Purpose: To report a case of multiple evanescent white dot syndrome (MEWDS) following adenovirus vector-based Coronavirus disease 2019 (COVID-19) vaccine, Covishield and to present a summary of previously reported cases of MEWDS following COVID-19 vaccines.

Methods: Retrospective case report and review of literature.

Results: A 22-year-old Indian female presented with blurred vision, scotomata, and photopsias in her left eye, a day after administration of second dose of Covishield vaccine. Her clinical findings and imaging features confirmed the diagnosis of MEWDS. Her symptoms resolved spontaneously after 2 weeks.

Conclusion: This is the first reported case of MEWDS following an adenovirus vector-based COVID-19 vaccine. Comparison with previously reported cases of MEWDS following COVID-19 vaccination showed that patients are generally healthy, young to middle-aged women, who develop symptoms after a median time of one week and recover spontaneously over a median period of 4 weeks.

Keywords: COVID-19; MEWDS; Oxford-AstraZeneca; multiple evanescent white dot syndrome; vaccine associated uveitis.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Adenoviridae / genetics
  • Adult
  • COVID-19 Vaccines* / adverse effects
  • COVID-19* / complications
  • ChAdOx1 nCoV-19
  • Female
  • Fluorescein Angiography
  • Fundus Oculi
  • Humans
  • Middle Aged
  • Retinal Diseases* / diagnosis
  • Retrospective Studies
  • Vision Disorders
  • White Dot Syndromes* / diagnosis
  • Young Adult

Substances

  • ChAdOx1 nCoV-19
  • COVID-19 Vaccines